Oruka Therapeutics
ORKA
79.50
-0.68
-0.85%
Oruka Therapeutics
US · ORKA
#2003 by market cap
Listed 1970
79.50
-0.68
-0.85%
Live - 5344 symbols - heartbeat 553s ago
· 2026-10-08 06:50
Pre-market
78.50
-1.26%
After-hours
79.50
0.00%
- Market cap
- 5.26B
- P/E (TTM)i
- -38.97
- P/Bi
- 4.74
- EPSi
- -1.85
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on ORKA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
154.50 +94.3%
Price target rangecurrent 79.50
Low120.00
Avg154.50
High200.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | BTIG | -- | BUY | 151.00 |
| 2026-09-24 | Wedbush | -- | BUY | 165.00 |
| 2026-09-24 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-09-23 | LifeSci Capital | -- | BUY | 175.00 |
| 2026-09-23 | Clear Street | -- | BUY | 131.00 |
| 2026-09-21 | Barclays | -- | BUY | 160.00 |
| 2026-09-09 | LifeSci Capital | -- | BUY | 175.00 |
| 2026-09-03 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-09-01 | UBS | -- | BUY | 130.00 |
| 2026-08-26 | TD Cowen | -- | BUY | -- |
| 2026-08-17 | Piper Sandler | -- | BUY | 180.00 |
| 2026-08-15 | LifeSci Capital | -- | BUY | 175.00 |
| 2026-08-11 | LifeSci Capital | -- | BUY | 175.00 |
| 2026-08-11 | Piper Sandler | -- | BUY | 180.00 |
| 2026-08-11 | Jefferies | -- | BUY | 133.00 |
| 2026-08-11 | Barclays | -- | BUY | 160.00 |
| 2026-08-10 | BTIG | -- | BUY | 151.00 |
| 2026-08-10 | Guggenheim | -- | BUY | 200.00 |
| 2026-08-03 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-07-31 | LifeSci Capital | -- | BUY | 125.00 |
| 2026-07-13 | BTIG | -- | BUY | 151.00 |
| 2026-07-02 | UBS | -- | BUY | 130.00 |
| 2026-07-01 | UBS | -- | BUY | 130.00 |
| 2026-06-29 | Stifel | -- | BUY | 150.00 |
| 2026-06-23 | H.C. Wainwright | -- | BUY | 120.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 06:50:07 · For reference only, not investment advice and not tailored to your situation.